Primary Outcome
- Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis [ Time Frame: Change from Baseline in SUVmax up to 1 week after talc pleurodesis. ] [ Designated as safety issue: No ]
Detailed Description
This is a single-center, open-label study, lasting 36 months including an estimated period of 24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at the end of three cycles of chemotherapy. A minimum number of 20 patients will be considered for the analysis.
Study Population
All patients affected by MPM and referred to our Institution for therapeutic pleurodesis and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. A minimum number of 20 patients will be considered for the analysis.
Eligibility
- Inclusion List
- patients with an histological diagnosis of MPM eligible for pleurodesis and scheduled to undergo platinum- and pemetrexed-based chemotherapy.
- obtained informed consent
- Exclusion Criteria
- patients age <18 years
- pregnancy or breast-feeding;
- patients affected by other malignancies within the last 3 years;